AZN Stock: AstraZeneca PLC Stock Price, Analysis & Insights
Get live azn stock price $82.40, comprehensive AstraZeneca PLC stock analysis, charts, news, and expert forecast. Real-time azn stock data and investment insights.
Loading chart...
Company Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company Information
- CEO
- Pascal Claude Roland Soriot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 94300
Contact Information
- Website
- https://www.astrazeneca.com
- Address
- 1 Francis Crick Avenue
- Country
- GB
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 255.4 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 31.1)
✓ Lower volatility stock (Beta: 0.17) may provide portfolio stability
Business Model & Strategy
AstraZeneca PLC operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a large-cap company, AstraZeneca PLC benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Pascal Claude Roland Soriot, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
AstraZeneca PLC competes in the Drug Manufacturers - General within the broader Healthcare. With 255.4 billion in market capitalization, the company is positioned as a market leader in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, AstraZeneca PLC provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating AstraZeneca PLC should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for AstraZeneca PLC shareholders
- ⚠Market volatility can significantly impact stock price, especially for large-cap equities
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for AstraZeneca PLC
- ⚠Investors should consider how AstraZeneca PLC fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 31.1) requires strong growth to justify
Market Cap
255.43B
P/E Ratio
31.09
Beta
0.17
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 255.43B market capitalization
- Trading Volume: 2.06M shares traded today
- Price Range: 52-week range of $61.24 - $86.57
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for AstraZeneca PLC
AstraZeneca PLC (AZN) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 255.43B, the company represents a significant player in its market. The stock is currently trading at $82.40 with a positivedaily change of 0.07%.
The company's 94300 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 31.09, beta of 0.17, and 52-week price range from $61.24 to $86.57when evaluating investment opportunities.
Why Invest in AstraZeneca PLC?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Pascal Claude Roland Soriot
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.